Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 3Unknown 1

Sponsor Class

OTHER 3UNKNOWN 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 57Lymphoid 19CNS 16Genitourinary 15Gastrointestinal 15Sarcoma 14Other hematologic neoplasm 13Thoracic 9Dermatologic 8Myeloid 5Gynecologic 5Endocrine 4Classical hematology 4NET 2Head & Neck 2Breast 2Tumor-Agnostic 1Other solid neoplasm 1

Conditions

Vipoma 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Somatostatinoma 1Neuroendocrine Tumors 1Neoplasms 1Lung Neoplasms 1Insulinoma 1Head and Neck Neoplasms 1Glucagonoma 1Gastrinoma 1Extrapancreatic Neuroendocrine Tumor 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1Adenocarcinoma, Follicular 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Thalidomide × Endocrine × Clear all
NCT03204032 2017-06-29

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

ChineseAMS

Phase 2 Unknown
60 enrolled
EndocrineGastrointestinalNET

Extrapancreatic Neuroendocrine Tumor

NCT00026533 2017-06-06

Thalidomide in Treating Patients With Thyroid Cancer

University of Kentucky

Phase 2 Completed
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

NCT00027638 2013-06-18

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
EndocrineThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00165230 2009-04-28

Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
32 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡